On the other hand, aprepitant acts as a liver enzyme (cytochrome P450 3A4) inhibitor that affects the metabolism of some cancer drugs and leads to an increase in blood concentration, causing adverse effects related to the drug used, i.e. Doxorubicin/Aprepitant. This evidence concerns the gene CYP3A4 and cancer.